Public Release:  Sugary bugs subvert antibodies

Rockefeller University Press

IMAGE

IMAGE: Researchers show how the body's antibody response can protect -- not destroy -- the bacterium Pseudomonas aeruginosa (pictured). view more

Credit: ©Kierbel, A., et al. 2007. J. Cell Biol. doi:10.1083/jcb.200605142

A lung-damaging bacterium turns the body's antibody response in its favor, according to a study published in The Journal of Experimental Medicine.

Pathogenic bacteria are normally destroyed by antibodies, immune proteins that coat the outer surface of the bug, laying a foundation for the deposition of pore-forming "complement" proteins that poke lethal holes in the bacterial membrane. But despite having plenty of antibodies and complement proteins in their bloodstream, some people can't fight off infections with the respiratory bacterium Pseudomonas aeruginosa. And chronic infection can lead to a condition called bronchiectasis, characterized by persistent cough, shortness of breath, and chest pain.

A group of researchers at the University of Birmingham, England, now find that the antibody response to Pseudomonas can get in its own way. In a subset of infected bronchiectasis patients with particularly poor lung function, they noticed an abundance of one specific type of antibody, called IgG2, which stripped the blood of its normal bug-killing capacity. The IgG2 proteins bound to extra-long sugars on the bacterial surface, a feature unique to the bugs infecting these patients. When these sugar-specific antibodies were removed, the blood's antibacterial prowess was restored.

Exactly how these IgG2 molecules protect the bug is unclear, but they may lure complement proteins away from more vulnerable parts of the bacterial surface. The discovery of antibodies that protect the bug instead of the person may help to explain why two vaccines based on these extra-long sugars resulted in worse disease in immunized individuals.

###

Wells, T.J., et al. 2014. J. Exp. Med. doi:10.1084/jem.20132444

About The Journal of Experimental Medicine

The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit http://www.jem.org .

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.